20.3 Site Readiness and Activity-Specific Release

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

20.3 Site Readiness and Activity-Specific Release

Key Takeaways Explain This Topic AI

Sponsor release labels are internal processes rather than universal regulatory definitions.

Shipment, screening, enrolment and dosing can have different prerequisites.

Critical readiness evidence must be verified before dependent activities.

Last updated: October 2026

Site Readiness and Activity-Specific Release

Note

Study Start-Up represents the critical operational bridge connecting site selection to active participant enrollment. The sponsor and monitor verify the relevant permissions, agreements, qualifications and operational readiness before each dependent activity. Shipment, training, screening, enrolment and dosing can have different prerequisites; apply the actual framework and documented release process.

In clinical research operations, initiating a site before it is genuinely prepared is a risk for protocol noncompliance and avoidable participant or data problems. The Site Initiation Visit (SIV) is not an informal meet-and-greet; it is a documented readiness and training activity where the investigative team is thoroughly educated on protocol requirements, drug safety reporting, investigational product handling, and Good Clinical Practice.

Coordinating start-up activities requires meticulous attention to essential documents, cross-departmental alignment, and absolute adherence to the sponsor's "Regulatory Green Light" process.

The Study Start-Up Continuum & The "Regulatory Green Light"

The Regulatory Green Light (also known as Authorization to Ship or Authorization to Enroll ) is the formal quality gate maintained by the sponsor's clinical quality assurance and regulatory affairs teams. It ensures that an investigative site has met the relevant readiness conditions across coordinated operational tracks:

The sponsor readiness gate

Follow the documented sponsor process and applicable prerequisites for each activity. Regulatory/ethics staff may verify the required decisions and agreements; operations confirms relevant qualification, training and readiness; supply functions release product under the appropriate conditions. The exact participants, sign-offs and names of gates depend on the trial and organisation. A particular US investigator form is not an international ICH requirement.

A sponsor’s internal authorisation does not replace required ethics or authority permission. Likewise, receiving an approval letter does not establish that staff, facilities, product and systems are ready. Document what the site is allowed to do, any restrictions and the evidence supporting the release. The monitor should not use one universal checklist to authorise activities whose prerequisites differ.

An unresolved critical safety or access problem should be addressed before the dependent activity. Lower-impact tasks can be managed according to an authorised plan when appropriate. Avoid claiming that every action item, however minor, always prohibits every activity; assess the actual requirement and risk. Keep decisions traceable so the site can distinguish permission to screen, enrol, dispense and dose.

Readiness evidence before affected activities

Use E6(R3) Appendix C and the trial's activation process. Verify current protocol and agreements, required ethics/authority decisions, approved participant materials, relevant IB/product instructions, qualifications, training, appropriate laboratory/technical evidence, product arrangements and fit-for-purpose systems. Some records apply only when relevant; a universal FDA 1572 package is not an international requirement.

Readiness area Evidence to examine Consequence of a gap

Ethics and authorisation Correct documents and versions covered by a valid decision Do not begin activities lacking required approval

People and training Qualified staff, investigator oversight and task preparation Complete required preparation before the task

Product and facilities Appropriate storage, accountability, supplies and contingency Resolve risks before release/use of affected product

Laboratory/diagnostics Suitable methods, reference ranges and required quality evidence Do not rely on unverified critical assessments

Systems and source access Attributable access, training and agreed records Resolve access/data risks before dependent activities

Financial/operational agreements Clear responsibilities, payments and injury arrangements Resolve conditions required by the agreement and activation plan

A conditional opinion requiring substantive changes is not final approval to begin. Likewise, a sponsor's internal release label is not itself regulatory approval. Establish the specific permission needed for each activity. Product shipment, site training and enrolment can have different prerequisites under the actual framework and sponsor procedure.

Preparing for and Conducting the Site Initiation Visit (SIV)

The Site Initiation Visit is conducted after essential documents are in place and IRB approval has been granted, either immediately prior to or upon receipt of investigational supplies.

Training the people who will perform the work

The investigator must understand and oversee the trial, and staff need training appropriate to their responsibilities before performing those activities. Attendance at one entire meeting by every named person is not a universal ICH rule. The sponsor may require PI attendance under its initiation procedure; apply that requirement accurately.

If the PI is unavailable, staff training or readiness review may still proceed under an appropriate plan. Do not declare the site ready until required investigator training and critical readiness conditions are satisfied and documented. Arrange remote or separate training where appropriate, retain evidence and confirm understanding. Distinguish meeting completion from authorisation to screen, enrol, dispense or dose.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .